Investor Presentaiton
For personal use only
Building a high-value diagnostics portfolio
"Breakthrough Therapy" designation, clinical leadership opportunity
•
•
•
Biologics License Application (BLA) consultation
process has commenced, Phase III study in final stages
of enrolment
TLX250-CDX is an investigational product being developed
for the imaging of clear cell renal cell carcinoma (ccRCC)
with PET/CT
Current options for patients are limited, potential for clinical
leadership with a non-invasive imaging modality for ccRCC
Being studied as an imaging agent assessing ability to
determine if "indeterminate renal masses" are malignant
through improved, whole of body imaging
May aid decision making and avoid unnecessary surgical
intervention
Opportunity to follow prostate cancer imaging, with a second
high-value product for the genitourinary (GU) oncology field
TELIX
PHARMACEUTICALS
An example of PET/CT imaging showing the uptake of
89Zr-girentuximab in a primary renal mass. The insert
shows the identification of a metastatic lesion of the
proximal radius, confirmed as ccRCC upon biopsy. 1
1. Hekman et al, European Urology. 2018.
Telix Pharmaceuticals Limited (ASX: TLX)
40View entire presentation